38 results about "Creatine kinase" patented technology

The invention provides a clinical rehabilitation data management and evaluation system for a rhabdomyolysis patient, and relates to a medical information management system. The system comprises an index acquisition module, a rate detection module, a curvature analysis module, a node identification module and a trend construction module. According to the method, the rate difference sequence of creatine kinase and myohemoglobin and the curvature sequence of urine sodium and serum creatinine are compositely calculated, the limitation of traditional single-parameter static analysis is broken through, the dynamic capture of a multi-index collaborative trend is realized, and a joint evolution label system is constructed by combining the consistency judgment of creatine kinase and blood potassium concentration change directions; according to the method, multi-system interaction risk nodes are accurately positioned, statistics is performed on direction consistency proportional distribution of myoglobin and serum creatinine in an association time period, discrete parameter association is converted into a dynamic visual model, and the problems of data discreteness misjudgment and collaborative evolution mode splitting in the traditional technology are solved. And a multi-dimensional dynamic evaluation framework of the rhabdomyolysis rehabilitation process is provided for clinic.

The invention belongs to the technical field of biological detection, and particularly discloses a cardiovascular marker substance control product and a preparation method thereof, the cardiovascular marker substance control product comprises a serum matrix, an antigen, a preservative and a stabilizer; the antigens comprise a cardiac troponin I antigen, a creatine kinase isoenzyme antigen, a myoglobin antigen, an amino-terminal brain natriuretic peptide precursor antigen, a brain natriuretic peptide antigen, a D-dimer antigen, a heart-type fatty acid binding protein antigen, a myeloperoxidase antigen and a lipoprotein phospholipase A2 antigen; the stabilizer comprises at least one of D-trehalose, cane sugar, glycine, inositol and polyethylene glycol. The cardiovascular marker substance control substance disclosed by the invention can cover various cardiovascular disease markers including heart failure, pulmonary artery embolism, vasculitis, atherosclerosis, myocardial injury, myocardial infarction and the like. The quality control product disclosed by the invention can be used as a third-party quality control product for screening cardiovascular diseases and performing indoor and interventricular quality control on an auxiliary diagnosis and measurement system.

The invention discloses combined probiotics for improving sarcopenia as well as a preparation method and application of the combined probiotics, and belongs to the field of probiotics. The invention relates to a combined probiotic for improving sarcopenia. The combined probiotic comprises a lactobacillus reuteri body, a lactobacillus johnsonii body, a lactobacillus fermentum body and a bifidobacterium adolescentis body. The combined probiotics disclosed by the invention can be used for remarkably improving the overall symptoms of sarcopenia model mice, including inhibiting weight loss, constipation symptoms and colonic mucosa destruction, prolonging load swimming time, improving muscle endurance, improving skeletal muscle atrophy, improving the expression of I-type slow muscle fiber protein MyHC I and promoting slow muscle fiber repair, and has the effects of preventing and treating sarcopenia. The invention discloses a probiotic intervention method for treating sarcopenia, which comprises the following steps of: preparing probiotics for treating sarcopenia, reducing the content of inflammatory cytokines in muscular tissues, increasing the content of hepatic glycogen, improving systematic metabolism of mice with sarcopenia and damaged serum markers, including lactic acid, lactic dehydrogenase, creatine kinase, creatinine, alanine transaminase ALT and aspartate transaminase AST, providing a new scheme for probiotic intervention for sarcopenia, and being used for preparing related functional products or intervention means.

The application discloses an evaluation method for predicting the safety of EGFR TKIs monotherapy for NSCLC. The method comprises the following steps: obtaining the data of a plurality of patients receiving EGFR TKIs treatment; taking MDRAE (maximum grade of drug-related adverse event) as a safety index, constructing a safety evaluation final model, and the final model is an ordered logistic regression model, the covariates of the final model include normalized steady-state trough concentration, EGFR TKIs treatment history, gender, baseline glutamyltransferase, baseline uric acid, baseline creatine kinase, baseline platelets and baseline lymphocytes; obtaining the data of a target patient, inputting the numerical values of each covariate in the data of the target patient into the final model; determining the first probability of MDRAE of the target patient being grade 3 and above, the second probability of MDRAE being grade 2 and the third probability of MDRAE being grade 1 and below according to the final model, and taking the grade corresponding to the maximum probability in the three probabilities as the predicted grade of MDRAE of the target patient. The application improves the accuracy of predicting the safety of EGFR TKIs monotherapy for NSCLC.

The invention discloses application of hydrogen-rich water in preparation of a drug for treating Duchenne type muscular dystrophy, and particularly relates to the technical field of medicines.The random control experiment is adopted, homologous c57 mice serve as a normal control group, mdx mice are randomly divided into a model group and a hydrogen-rich water group, and the exercise ability is evaluated through a four-limb holding power test and a rotating bar test; detecting mouse creatine kinase by an enzyme-linked immunosorbent assay; carrying out hematoxylin-eosin, NADH-tetrazole reductase and improved Goori three-color dyeing, and carrying out cytochrome C oxidase, succinate dehydrogenase and SDH-COX combined dyeing to observe the pathological change of the skeletal muscle tissue; the invention discloses that the muscle injury condition of a Duchenne type muscular dystrophy model mouse is improved by the hydrogen-rich water through a mitochondrial protection mechanism, and the hydrogen-rich water has a relatively high application prospect and a relatively high economic value.

The present invention relates to an anti-tumor use of a phosphorus compound. Specifically, the present invention provides a use of a compound of formula (I), an optical isomer thereof, a racemate thereof, a solvate thereof, a pharmaceutically acceptable salt thereof or a deuterated compound thereof in preparation of a composition or a preparation, wherein the composition or the preparation is used for preventing and / or treating tumors. The compound of the present invention exhibits excellent precise therapeutic efficacy against tumors characterized by high expression of kinase B.

The invention belongs to the technical field of protein peptide preparation, and particularly relates to wheat oligopeptide with an anti-fatigue effect and a preparation method of the wheat oligopeptide. According to the method, the raw materials are subjected to enzymolysis by using the first compound enzyme containing bacillus subtilis protease and bromelain and the second compound enzyme containing trypsin, flavourzyme and papain step by step, and treatment of centrifugation, ultrafiltration and the like is combined, so that the yield and the taste of the product are improved, and the proportion of small molecular weight peptide in the product is high. Therefore, the wheat oligopeptide prepared by the method is high in yield and good in taste, not only is beneficial to improving the endurance of the body and prolonging the exercise time, but also can improve the energy metabolism condition in the body, delay the accumulation of lactic acid, urea nitrogen and creatine kinase in the body after exercise and increase the glycogen storage amount, and macroscopically shows certain anti-fatigue ability. The technical scheme of the invention has strong practicability, is beneficial to industrial production, and can be applied to preparation of anti-fatigue functional food.

The invention provides a fish creatine kinase sensitization and immune cross reactivity analysis method which comprises the following steps: preparing a fish muscle water-soluble protein crude extract, separating 40-45kDa protein components in the fish muscle crude extract through SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis), and screening a target sensitization protein combined with IgE / IgG through immunoblotting; the method comprises the following steps: extracting total RNA of grass carp and synthesizing cDNA, designing a creatine kinase specific primer for amplification to obtain a creatine kinase gene sequence, and carrying out bioinformatics analysis after sequencing verification; the method comprises the following steps: cloning a creatine kinase gene to an expression vector, transforming escherichia coli BL21, performing IPTG induced expression, and performing urea gradient dialysis renaturation on an inclusion body to obtain the recombinant grass carp creatine kinase. Detecting the IgE binding activity of the recombinant grass carp creatine kinase and the serum of the allergic patient through dot hybridization; the IgG cross reactivity of the recombinant grass carp creatine kinase and the blue crab arginine kinase is verified through indirect ELISA; the IgE cross reaction degree of the recombined grass carp creatine kinase and the blue crab arginine kinase is quantified through inhibitory dot hybridization.

The invention relates to application of a Fe < 3 + >-ATP-CK cascade regulation type carbon dot fluorescent probe in dynamic monitoring of creatine kinase content, and relates to the field of new application of carbon dots. Fluorescence of B, N-CDs is quenched by Fe < 3 + >, and then fluorescence is recovered after ATP is added through specific binding of Fe < 3 + > and ATP. When CK catalyzes ATP to react with Cr, fluorescence is quenched again due to reduction of the ATP content. On the basis of high-selectivity competitive combination of Fe < 3 + > and ATP, interference of ADP, AMP and other analogues can be eliminated. The multiple verification mechanisms of Fe < 3 + > quenching, ATP recovery and CK re-quenching significantly reduce the false positive result, and enhance the detection reliability. A portable sensing platform constructed based on a smart phone establishes a new method for bedside detection of CK, establishes a brand new strategy for CK detection, and shows a wide prospect in rapid screening application of clinical diagnosis of myocardial infarction and the like.

The invention discloses a traditional Chinese medicine composition for treating ischemic diseases of lower limbs and also provides a preparation method of the traditional Chinese medicine composition, the synergistic combination effect of the two medicines is exerted, the curative effect of a single medicine is obviously improved, and the anticoagulant effect is far greater than that of the independent administration of caltrop; the sum of the action intensity of two independent administration is achieved, and the in-vitro anticoagulation effect and the effect of improving the ischemic blood flow of the lower limbs can be remarkably improved; blood vessel growth factors are remarkably increased, the activity of creatine kinase and lactic dehydrogenase is reduced, and tissue damage is relieved; glutathione peroxidase is promoted, malondialdehyde and active oxygen are inhibited, and the anti-oxidation effect is achieved; hypoxia and mitochondrial functions can be improved by inhibiting hypoxia-inducible factors (hypoxia-inducible factors)-1 alpha and mitochondrial compounds 3; the anti-inflammatory effect can be achieved by inhibiting CRP, IL-1beta and TNF-alpha; the rat lower limb ischemia can be obviously improved and treated.

The traditional Chinese medicine composition is characterized by being prepared from the following traditional Chinese medicinal materials in parts by weight: 3 to 9 parts of rhizoma chuanxiong, 3 to 7 parts of rhizoma atractylodis, 6 to 14 parts of rhizoma cyperi, 6 to 14 parts of medicated leaven, 3 to 7 parts of euphorbia helioscopia, 10 to 20 parts of poria cocos, 8 to 12 parts of fructus trichosanthis, 8 to 12 parts of radix salviae miltiorrhizae, 8 to 12 parts of herba epimedii, 3 to 9 parts of pepper, 8 to 12 parts of herba patriniae and 8 to 12 parts of caulis spatholobi. After the traditional Chinese medicine composition is used for treating acute myocardial infarction, a remarkable effect is achieved on PCI postoperative improvement of acute myocardial infarction, troponin and creatine kinase isoenzyme indexes are reduced, and the left ventricular ejection fraction is in a normal range after cardiac color ultrasound display treatment. Through comprehensive conditioning, symptoms such as chest distress, chest pain, shortness of breath and hypodynamia of patients are improved, cardiac function recovery is promoted, complications such as restenosis and heart failure are prevented, and life quality is improved.

The invention discloses an evaluation method for predicting the safety of EGFR TKIs (epidermal growth factor receptor TKIs) single-drug treatment on NSCLC (non-small cell carcinoma). The method comprises the following steps: acquiring data of a plurality of patients receiving EGFR TKIs treatment; the method comprises the following steps of: constructing a safety assessment final model by taking MDRAE (Maximum Grade Of Related Adverse Event) as a safety index, the final model is an ordered logic regression model, and the covariables of the final model comprise normalized steady-state valley concentration, EGFR TKIs treatment history, gender, baseline glutamyltransferase, baseline uric acid, baseline creatine kinase, baseline platelet and baseline lymphocyte; obtaining target patient data, and inputting each covariable value in the target patient data into the final model; and according to the final model, determining a first probability that the MDRAE of the target patient is at a level 3 or above, a second probability that the MDRAE is at a level 2, and a third probability that the MDRAE is at a level 1 or below, and taking a level corresponding to a maximum probability value in the three probabilities as an MDRAE prediction level of the target patient. According to the invention, the accuracy of predicting the safety of EGFR TKIs single-drug treatment on NSCLC is improved.

The application provides a clinical rehabilitation data management and evaluation system for rhabdomyolysis patients, and relates to a medical information management system.The system comprises an index acquisition module, a rate detection module, a curvature analysis module, a node identification module and a trend construction module.In the application, the rate difference sequence of creatine kinase and myoglobin and the curvature sequence of urine sodium and blood creatinine are combined to break through the limitations of traditional single-parameter static analysis, realize dynamic capture of multi-index collaborative trend, construct a joint evolution label system by combining the consistency discrimination of creatine kinase and blood potassium concentration change direction, accurately locate the multi-system interaction risk nodes, and statistically distribute the direction consistency proportion of myoglobin and blood creatinine in the correlation period, so as to convert the discrete parameter correlation into a dynamic visual model.The method solves the problems of data dispersion misjudgment and collaborative evolution mode fragmentation in the traditional technology, and provides a multi-dimensional dynamic evaluation framework for the rhabdomyolysis rehabilitation process in clinical practice.

The invention relates to a pharmaceutical application of nardosinone in prevention and treatment of cardiotoxicity, in particular to an application of nardosinone in prevention or treatment of cardiotoxicity caused by anthracycline antitumor drugs. Experiments prove that nardosinone has a remarkable curative effect on mouse myocardial injury caused by doxorubicin, and can be used for remarkably increasing the left ventricular ejection fraction and the short-axis shortening rate of the mouse heart caused by DOX (doxorubicin); the release amount of lactic dehydrogenase and creatine kinase in mouse plasma caused by DOX is reduced, the mouse myocardial fibrosis caused by DOX is reduced, and myocardial cell apoptosis and endoplasmic reticulum stress injury caused by DOX are relieved. The nardosinone is low in raw material cost and easy to obtain, can be used as an active component or a medicine composition component for myocardial protection of anthracycline chemotherapy medicines, and has a good medication prospect.

The present disclosure generally provides compositions and methods for increasing the activity of an annexin protein to treat a cellular membrane injury in a patient in need thereof. In some aspects, the disclosure provides methods of treating a patient suffering from a nerve injury comprising administering a therapeutically effective amount of a composition comprising an agent that increases the activity of an annexin protein. In further aspects, the disclosure provides methods of reducing serum or plasma level of lactate dehydrogenase (LDH), cardiac troponin T, cardiac troponin I, creatine kinase (CK), or a combination thereof, in a patient in need thereof, comprising administering a therapeutically effective amount of an agent that increases the activity of an annexin protein to the patient.

The invention relates to the technical field of traditional Chinese medicine agentia, and particularly discloses a traditional Chinese medicine compound anti-fatigue agentia based on American ginseng and a preparation method, the traditional Chinese medicine compound anti-fatigue agentia comprises the following components in parts by mass: 5-10 parts of American ginseng, 10-20 parts of pericarpium citri reticulatae, 10-20 parts of fructus lycii, 4-8 parts of schisandra chinensis, 8-16 parts of Chinese yam, 4-8 parts of bighead atractylodes rhizome, 5-10 parts of rhizoma alismatis, 10-20 parts of radix ophiopogonis, 0.5-1.5 parts of parasitic loranthus, 2-6 parts of radix aconiti carmichaeli, 5-8 parts of fresh ginger, 3-9 parts of lucid ganoderma and 4 According to the traditional Chinese medicine composition, the content of glycogen in a human body is increased, the content of lactic acid, urea nitrogen and creatine kinase in the human body is reduced, a good anti-fatigue effect is achieved, an extracting solution prepared from traditional Chinese medicine components has a green and healthy treatment effect on the human body, and impurities which are useless and harmful to the human body can be removed in a distillation and purification mode.

The invention discloses an application of capsaicin in improving fish meat quality, and belongs to the technical field of aquaculture. The improvement of the fish meat quality by capsaicin is realized by improving the meat yield, increasing the crude protein content, slowing down the pH decreasing amplitude, reducing the cooking loss, improving the hardness, improving the freshness, increasing the sweet taste and the salty taste, inhibiting the generation of methyl mercaptan and ethanethiol, promoting the synthesis of fresh flavor substances, increasing the contents of ATP, Ca < 2 + >-Mg < 2 + >-ATPase, creatine kinase, HK and glycogen and reducing the lactic acid content. By adding low-dose capsaicin into the fish feed for feeding fish, the flavor quality of aquatic products can be effectively improved, and technical support is provided for application of low-dose natural additives in the field of aquatic product preservation and aroma enhancement.

This invention provides a method for site-specific replacement of the creatine kinase promoter in the Huaxi bovine gene promoter, belonging to the field of animal gene editing and genetic breeding technology. It also provides a method for enhancing the function of bovine muscle cells. FTO Gene expression reagents include crRNA for upstream site knockout, crRNA for downstream site knockout, a Cas12i nuclease expression vector, and an FTO homologous substitution vector; the FTO homologous substitution vector includes... FTO upstream homologous arm of gene promoter, MCK gene promoter and FTO Downstream homologous arm of the gene promoter. The reagent was used in West China bovine cells. FTO Application in gene promoter replacement. This invention can specifically improve the expression efficiency of genes related to fat development in muscle tissue, providing an efficient and precise technical means for the genetic improvement of the performance of beef from Western China.

The invention discloses a lactobacillus rhamnosus CQFP202457 and application of the lactobacillus rhamnosus CQFP202457 in relieving exercise-induced fatigue, and belongs to the field of microorganisms. The invention provides a lactobacillus rhamnosus CQFP202457, and the preservation number of the lactobacillus rhamnosus CQFP202457 is CGMCC (China General Microbiological Culture Collection Center) No.29784. The lactobacillus rhamnosus CQFP202457 can be used for preparing the lactobacillus rhamnosus CQFP202457. The invention also provides application of the strain in preparation of a composition for relieving exercise-induced fatigue. Experimental results show that the lactobacillus rhamnosus CQFP202457 can significantly prolong exhaustion exercise time, improve exercise tolerance, reduce levels of lactic acid, urea nitrogen and creatine kinase in serum after exercise, reduce accumulation of exercise metabolites and relieve muscle injury. The invention provides a new microbial resource for developing a product for relieving exercise-induced fatigue.

The present invention relates to compounds of Formula (I): or a pharmaceutically acceptable salt thereof useful for treatment of a disease or disorder associated with CK and methods of inhibiting CK.

The invention provides application of a traditional Chinese medicine composition in preparation of a medicine for treating or preventing idiopathic inflammatory myopathy. The traditional Chinese medicine composition comprises the following components in parts by weight: 1-100 parts of mangnolia officinalis, 1-100 parts of scorched betel nut, 1-100 parts of roasted amomum tsao-ko, 1-100 parts of ephedra, 1-100 parts of semen armeniacae amarae, 1-100 parts of notopterygium root, 1-100 parts of ginger, 1-100 parts of pogostemon cablin, 1-100 parts of eupatorium, 1-100 parts of rhizoma atractylodis, 1-160 parts of poria cocos, 1-120 parts of bighead atractylodes rhizome, 1-100 parts of gypsum, 1-100 parts of scorched hawthorn fruit, 1-100 parts of scorched medicated leaven, 1-100 parts of scorched malt, 1-100 parts of earthworm, 1-100 parts of cynanchum paniculatum, 1-100 parts The traditional Chinese medicine composition can improve the disease symptoms of idiopathic myopathy model rats, reduce the levels of creatine kinase, lactic dehydrogenase and glutamic oxalacetic transaminase in serum of the rats, has a certain regulation effect on the time limit and amplitude of guinea pig electromyogram, can also reduce the activity of creatine phosphokinase, lactic dehydrogenase and glutamic oxalacetic transaminase of the rats, and can improve the curative effect of the rats. The traditional Chinese medicine composition is proved to have a treatment effect on idiopathic inflammatory myopathy.

The application discloses application of brain-type creatine kinase in preparation of a medicine for preventing or treating Parkinson's disease, belongs to the technical field of genetic engineering, and provides the application of brain-type creatine kinase in preparation of the medicine for preventing or treating Parkinson's disease, wherein the amino acid sequence of the brain-type creatine kinase is shown as SEQ ID NO. 6. The application of brain-type creatine kinase as a treatment target in screening of the medicine for preventing or treating Parkinson's disease. The application firstly finds that in a Parkinson's disease mouse model, reducing expression of brain-type creatine kinase (CKB) increases loss and death of dopaminergic neurons in the substantia nigra pars compacta of the Parkinson's disease mouse, and significantly aggravates motor dysfunction of the Parkinson's disease mouse; overexpression of CKB obviously reduces damage of Parkinson's disease neurons. The CKB protein is a new target for preventing and treating Parkinson's disease, can be used for screening and finding the medicine for preventing and treating Parkinson's disease, can inhibit death of dopaminergic neurons by improving CKB expression, and realizes the effect of preventing and treating Parkinson's disease.

The present invention relates to the technical field of sports fatigue monitoring, and discloses a sports fatigue monitoring device based on blood detection, including a monitor, a detection gun, a partition, a chamber 1, a chamber 2, a telescopic motor 1, a telescopic rod, a horizontal rod, a vertical rod, a testosterone detection module, a cortisol detection module, a creatine kinase detection module, a urea detection module, a rotating motor, a rotating shaft, a placement plate, a holding dish, a blood sample socket, a chamber 3, a conveyor belt, a hemoglobin detection module, a chamber 4, a tooth-shaped button, a pressure-sensitive switch 1 and a pressure-sensitive switch 2. The present invention comprehensively analyzes the degree of sports fatigue by detecting the ratio of testosterone to cortisol, the content of creatine kinase, the content of urea and the content of hemoglobin in serum, realizes the monitoring of post-exercise fatigue and the quantitative display of indicators of the degree of sports fatigue, and provides a scientific basis for the guidance of sports training through planned and long-term detection and analysis.

This invention belongs to the field of biomedical technology, specifically relating to a composition for treating ischemic heart disease and its application. This invention combines two or more of ginsenoside Rg1, ginsenoside Rb1, ginsenoside Re, and notoginsenoside R1, which can significantly downregulate the levels of myocardial enzymes, aspartate aminotransferase (AST), creatine kinase (CK), and lactate dehydrogenase (LDH) in myocardial coronary effusion, with an inhibitory effect significantly higher than that of a single saponin component and the positive control drug verapamil. Simultaneously, the composition exhibits better recovery capabilities for coronary flow (CF), left ventricular developmental pressure (LVDP), maximum rate of decrease in left ventricular pressure (-dp / dtmax), and heart rate (HR) in myocardial coronary effusion. Therefore, the composition can alleviate and treat myocardial ischemia-reperfusion injury through multiple targets and mechanisms, fundamentally inhibiting the development of ischemic heart disease.

The invention discloses an application of H1152 in preparation of a medicine for treating metabolism-related cognitive impairment, belongs to the technical field of medicine, breaks through the limitation that an existing medicine singly regulates metabolism or cognition, and the H1152 can synchronously inhibit abnormal weight growth induced by high fat diet and remarkably improve spatial memory water maze experiments and short-term memory new object recognition experiments. Dual intervention of metabolism and nerves is realized; compared with statins, the H1152 does not observe creatine kinase rise or liver enzyme abnormity under the equivalent lipid-lowering dosage, and animal experiments show that the H1152 has better safety; the ROCK signal channel is regulated and controlled, and the ROCK signal channel acts on vascular endothelial function improvement and neuronal synaptic plasticity enhancement at the same time, so that the problem of co-disease of metabolism and cognition is solved from the multi-target level; the body weight growth rate, the water maze escape latency and the new object recognition index are integrated as the combined curative effect markers for the first time, and quantifiable objective standards are provided for clinical curative effect evaluation.

The invention belongs to the technical field of bioengineering, and particularly relates to a prokaryotic cell-free translation system buffer solution and application thereof. The prokaryotic cell-free translation system buffer solution comprises HEPES-KOH (pH 8.0), magnesium glutamate, ATP (adenosine triphosphate), GTP (glutathione triphosphate), potassium glutamate, creatine kinase and creatine phosphate. According to the present invention, the research accidentally discovers that the translation efficiency of the prokaryotic acellular translation system buffer solution constructed after the reduction of 28 unnecessary components is substantially the same as the translation efficiency of the original report, and the translation efficiency of the prokaryotic acellular translation system is significantly improved after the concentration is optimized, such that the good practical application value and the good prospect are provided.

The invention relates to the technical field of bioengineering, in particular to a preparation method of stable natural creatine kinase. Comprising the following steps: removing fascia fat from a pig heart, adding a DK1 buffer solution, and crushing by a meat grinder to obtain an enzyme extracting solution A; adding ammonium sulfate into the crude enzyme extract A for multiple times, adjusting the pH value by using DK2, centrifuging, and taking supernatant to obtain an enzyme extract B; adding solid ammonium sulfate into the enzyme extracting solution B to carry out salting-out precipitation, centrifuging to take precipitate, and dialyzing with DK2 to obtain an enzyme extracting solution C; purifying through an ion exchange column, and sequentially eluting through a DK3 buffer solution to obtain a creatine kinase solution; carrying out concentration dialysis liquid change treatment on creatine kinase by using DK4 to obtain an enzyme extracting solution D; adding a liquid protective agent into the enzyme extracting solution, and carrying out stabilizer research; through the mode, high-activity and high-stability creatine kinase can be obtained, the process repeatability is high, the cost is low, and large-scale production of the process is facilitated.

The invention belongs to the technical field of medical prediction models, and particularly relates to a risk prediction model based on idiopathic inflammatory myopathy merged malignant tumors and application. Comprising 12 risk factors: elderly, male sex, DM subtype, interstitial lung disease, arthritis, fever, Reynolds phenomenon, dysphagia, Gotron rash, skin necrosis, creatine kinase elevation and anti-transcription intermediary factor 1 (TIF1 gamma) antibody. According to the risk prediction model based on idiopathic inflammatory myopathy and malignant tumors, meta analysis is performed by integrating data of 57 studies, the reliability and universality of cancer risk factors are enhanced, the sample size is remarkably increased, and the result robustness is ensured. The evaluation risk score has high performance in predicting the risk of merging the tumors in the IIM patient, and the AUC can reach 0.86.

The invention relates to the technical field of medical diagnosis, and provides a biomarker, a reagent and a kit for early recognition of metastatic lung cancer and application, the biomarker is a creatine kinase-brain type (CKB) molecule, and the CKB molecule highly expressed in platelets is an important energy source for circulating tumor cells to maintain survival and realize hematogenous metastasis. By detecting the expression quantity of CKB in serum or platelets, the metastatic lung cancer is expected to be recognized in an early stage.

The invention discloses a feed additive and application. The feed additive contains anthocyanin and methyl caffeate. Experimental data show that the feed additive can significantly reduce body temperature rise caused by heat stress, significantly reduce stress indexes such as C-reactive protein, creatine kinase, malondialdehyde and the like in dogs, and can effectively relieve the heat stress of the dogs. Meanwhile, the feed additive is low in raw material cost and easy to prepare and use, and has a good economic benefit prospect.